The long-term goal of this laboratory is to define the growth control mechanisms of malignant human gliomas (MHG). We believe that losses of function of specific genes (suppressor genes) through chromosomal loss, deletion, or mutation are critical steps in the evolution of these tumors. Our goals are to identify tumor suppressor genes which are important in human gliomas and to determine in which histologic stages of glioma progression alterations of these suppressor genes occur.
In specific aim (1), specific chromosomes and chromosomal regions which are lost in different histologic grades of gliomas will be identified by a combination of allelotyping and karyotyping of astrocytomas, anaplastic astrocytomas and glioblastomas (GBM) to define the locations of genetic losses associated with glioma progression. These studies will establish the basis for assessing the role of known tumor suppressor genes located in these regions and will provide the starting point for ultimately isolating new genes from locations which contain no known suppressor genes. Chromosomal and molecular studies have shown that loss of chromosome 10 occurs in most GBM but the gene located on this chromosome which is inactivated in gliomas has not been identified or regionally localized.
In specific aim (2), the region of chromosome 10 which is lost in MHG will be defined, constituting a major step toward the eventual isolation of a suppressor gene from this location. Specifically, a panel of polymorphic probes will be isolated from a chromosome 10 genomic library and regionally mapped. The region of chromosome 10 which is lost in MHG will be defined using microcell-mediated transfer of complete and fragments of human chromosome 10 and RFLP analysis of a large series of karyotyped GBM.
In specific aim (3), the role of known tumor suppressor genes will be determined in human gliomas. Normal copies of the p53 gene will be transfected into glioma cell lines with p53 gene mutations and normal copies of the retinoblastoma gene will be transfected into glioma lines which do not express this gene to determine if restoration of these normal genes reverses tumorigenicity, prevents growth in soft agar, or produces senescence. These studies will determine whether alterations of known tumor suppressor genes are critical to the development of human gliomas and will identify regions of chromosomal loss which are likely to harbor new tumor suppressor genes which contribute to the genesis and progression of these tumors. Definition of these regions of chromosomal loss will form the basis for the eventual isolation of the relevant suppressor genes in these locations. Characterization of these genes will elucidate regulatory mechanisms which are operative in repair, regeneration, development and differentiation of normal cells and these genes and antibodies against their products are potentially useful in the clinical and histological diagnosis and classification of human brain tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA043722-07
Application #
3482552
Study Section
Pathology A Study Section (PTHA)
Project Start
1987-01-01
Project End
1995-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Rasheed, B K; McLendon, R E; Herndon, J E et al. (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-30
Fuller, G N; Bigner, S H (1992) Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 276:299-306
Bigner, S H (1992) Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 51:235-45
Rasheed, B K; Fuller, G N; Friedman, A H et al. (1992) Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer 5:75-82
Fuchs, H E; Archer, G E; Colvin, O M et al. (1990) Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50:1954-9
Bigner, S H; Mark, J; Bigner, D D (1990) Cytogenetics of human brain tumors. Cancer Genet Cytogenet 47:141-54
Fredman, P; Mansson, J E; Bigner, S H et al. (1990) Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats. Biochim Biophys Acta 1045:239-44
Bigner, S H (1990) Molecular probes in neuro-oncology: the future. Cancer Invest 8:445-6
Bigner, S H; Schold, S C; Friedman, H S et al. (1989) Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. Cancer Genet Cytogenet 40:111-20
Rosenberg, M C; Colvin, O M; Griffith, O W et al. (1989) Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Res 49:6917-22

Showing the most recent 10 out of 16 publications